Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVHD-Reduction Strategies for Allogeneic PBSCT in Acute Leukemia or MDS
NCT03970096Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CD45RA-depleted peripheral blood stem cells, cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Started Nov 2019; status: recruiting.
02
Drugs
CD45RA-depleted peripheral blood stem cellscyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03970096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970096.